•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
Aurora Cannabis Stock Has Soared 25% Since Curaleaf First Made an Offer to Buy Its Business. Here's Why I Think It Can Go Even Higher
Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease
Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output
Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway
Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile Bid
Aurora Cannabis (TSE:ACB) Shares Up 15.6% – Still a Buy?
Aurora Cannabis Sees Unusually High Options Volume (NASDAQ:ACB)
Curaleaf raises Aurora Cannabis offer by 25%
Comparing ProPhase Labs (NASDAQ:PRPH) and Aurora Cannabis (NASDAQ:ACB)
Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.
Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure
Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond
Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts
Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts
$250,000 in These 3 High-Income ETFs Could Pay You ~$2,800 a Month
Already premium?